Recent studies using [18F]-fluorodeoxyglucose (FDG) PET demonstrated altered brain metabolism in GBA1-PD compared with LRRK2-PD and sPD, underlying a more aggressive disease in GBA1-PD patients [82, 83]. This evidence concerns the gene GBA1 and Parkinson disease.